BE2018C008I2 - - Google Patents

Download PDF

Info

Publication number: BE2018C008I2
Authority: BE; Belgium
Prior art keywords: represent; alkoxy; present; compounds; solvates
Prior art date: 2001-04-27

Application number

BE2018C008C

Other languages

English (en)

Dutch (nl)

Original Assignee

Kyowa Hakko Kirin Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-04-27

Filing date

2018-02-08

Publication date

2021-02-04

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=18980738&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2018C008(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2018-02-08 Application filed by Kyowa Hakko Kirin Co Ltd filed Critical Kyowa Hakko Kirin Co Ltd

2021-02-04 Publication of BE2018C008I2 publication Critical patent/BE2018C008I2/nl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Heart & Thoracic Surgery (AREA)
Rheumatology (AREA)
Cardiology (AREA)
Emergency Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Obesity (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Pain & Pain Management (AREA)
Endocrinology (AREA)
Ophthalmology & Optometry (AREA)
Immunology (AREA)
Hematology (AREA)
Physical Education & Sports Medicine (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Luminescent Compositions (AREA)
Adhesives Or Adhesive Processes (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Polymerization Catalysts (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

BE2018C008C 2001-04-27 2018-02-08 BE2018C008I2 (it)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2001132775		2001-04-27
PCT/JP2002/004279 WO2002088110A1 (en)	2001-04-27	2002-04-26	Quinoline derivative having azolyl group and quinazoline derivative

Publications (1)

Publication Number	Publication Date
BE2018C008I2 true BE2018C008I2 (it)	2021-02-04

Family

ID=18980738

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BE2018C008C BE2018C008I2 (it)	2001-04-27	2018-02-08

Country Status (24)

Country	Link
US (2)	US6821987B2 (it)
EP (2)	EP1652847B1 (it)
JP (1)	JP2010077131A (it)
KR (1)	KR100879669B1 (it)
CN (1)	CN1273466C (it)
AT (1)	ATE396988T1 (it)
AU (1)	AU2002255284B2 (it)
BE (1)	BE2018C008I2 (it)
BR (1)	BRPI0209216B8 (it)
CA (1)	CA2445333C (it)
DE (2)	DE60226912D1 (it)
DK (1)	DK1382604T3 (it)
ES (1)	ES2256466T3 (it)
FR (1)	FR18C1006I2 (it)
IL (1)	IL158459A0 (it)
MX (1)	MXPA03009662A (it)
NL (1)	NL300927I9 (it)
NO (2)	NO326325B1 (it)
NZ (1)	NZ529046A (it)
PL (1)	PL209822B1 (it)
RU (1)	RU2283841C2 (it)
TW (1)	TWI324154B (it)
WO (1)	WO2002088110A1 (it)
ZA (1)	ZA200307861B (it)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2000043366A1 (en) *	1999-01-22	2000-07-27	Kirin Beer Kabushiki Kaisha	Quinoline derivatives and quinazoline derivatives
US7135466B2 (en) *	1999-12-24	2006-11-14	Kirin Beer Kabushiki Kaisha	Quinoline and quinazoline derivatives and drugs containing the same
US7312044B2 (en)	2003-03-07	2007-12-25	The Trustees Of Columbia University In The City Of New York	Type 1 ryanodine receptor-based methods
US8022058B2 (en)	2000-05-10	2011-09-20	The Trustees Of Columbia University In The City Of New York	Agents for preventing and treating disorders involving modulation of the RyR receptors
US7879840B2 (en)	2005-08-25	2011-02-01	The Trustees Of Columbia University In The City Of New York	Agents for preventing and treating disorders involving modulation of the RyR receptors
US7718644B2 (en)	2004-01-22	2010-05-18	The Trustees Of Columbia University In The City Of New York	Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
US7393652B2 (en)	2000-05-10	2008-07-01	The Trustees Of Columbia University In The City Of New York	Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2)
US20040229781A1 (en) *	2000-05-10	2004-11-18	Marks Andrew Robert	Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias
US20040048780A1 (en) *	2000-05-10	2004-03-11	The Trustees Of Columbia University In The City Of New York	Method for treating and preventing cardiac arrhythmia
US20060293266A1 (en) *	2000-05-10	2006-12-28	The Trustees Of Columbia	Phosphodiesterase 4D in the ryanodine receptor complex protects against heart failure
US6489125B1 (en) *	2000-05-10	2002-12-03	The Trustees Of Columbia University In The City Of New York	Methods for identifying chemical compounds that inhibit dissociation of FKBP12.6 binding protein from type 2 ryanodine receptor
DE60137273D1 (de) *	2000-10-20	2009-02-12	Eisai R&D Man Co Ltd	Verfahren zur Herstellung von 4-Phenoxy chinolin Derivaten
WO2002088110A1 (en)	2001-04-27	2002-11-07	Kirin Beer Kabushiki Kaisha	Quinoline derivative having azolyl group and quinazoline derivative
US7425564B2 (en) *	2001-06-22	2008-09-16	Kirin Beer Kabushiki Kaisha	Quinoline derivative and quinazoline derivative inhibiting self-phosphorylation of hepatocytus prolifertor receptor and medicinal composition containing the same
EP1447405A4 (en) *	2001-10-17	2005-01-12	Kirin Brewery	CHINOLIN OR CHINAZOLINE DERIVATIVES THAT PREVENT THE AUTOPHOSPHORYLATION OF RECEPTORS FOR THE FIBROBLAST GROWTH FACTOR
AU2003235838A1 (en) *	2002-05-01	2003-11-17	Kirin Beer Kabushiki Kaisha	Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of macrophage colony stimulating factor receptor
US7576074B2 (en)	2002-07-15	2009-08-18	Rice Kenneth D	Receptor-type kinase modulators and methods of use
DE60316590T2 (de)	2002-10-21	2008-06-19	Kirin Beer K.K.	N-(2-CHLOR-4-((6,7-DIMETHOXY-4-CHINOLYL)OXYÜPHENYLü-N'-(5-METHYL-3-ISOXAZOLYL)HARNSTOFFSALZIN KRISTALLINER FORM
AU2003280599A1 (en) *	2002-10-29	2004-05-25	Kirin Beer Kabushiki Kaisha	QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES INHIBITING AUTOPHOSPHORYLATION OF Flt3 AND MEDICINAL COMPOSITIONS CONTAINING THE SAME
US7544678B2 (en)	2002-11-05	2009-06-09	The Trustees Of Columbia University In The City Of New York	Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
WO2004060373A1 (ja) *	2002-12-27	2004-07-22	Santen Pharmaceutical Co., Ltd.	滲出型加齢黄斑変性治療剤
JPWO2004080462A1 (ja) *	2003-03-10	2006-06-08	エーザイ株式会社	ｃ−Ｋｉｔキナーゼ阻害剤
PL2210607T3 (pl) *	2003-09-26	2012-01-31	Exelixis Inc	N-[3-fluoro-4-({6-(metyloksy)-7-[(3-morfolin-4-ylopropylo)oksy]chinolin-4-ylo} oxy)fenylo]-N'-(4-fluorofenylo)cyklopropano-1,1-dikarboksamid do leczenia raka
CN100450998C (zh)	2003-11-11	2009-01-14	卫材R&D管理有限公司	脲衍生物的制备方法
WO2005048953A2 (en) *	2003-11-13	2005-06-02	Ambit Biosciences Corporation	Amide derivatives as kinase modulators
US8710045B2 (en)	2004-01-22	2014-04-29	The Trustees Of Columbia University In The City Of New York	Agents for preventing and treating disorders involving modulation of the ryanodine receptors
EP1711495A2 (en) *	2004-01-23	2006-10-18	Amgen Inc.	Quinoline, quinazoline, pyridine and pyrimidine counds and their use in the treatment of inflammation, angiogenesis and cancer
TW200530236A (en)	2004-02-23	2005-09-16	Chugai Pharmaceutical Co Ltd	Heteroaryl phenylurea
EP1797881B1 (en)	2004-09-17	2009-04-15	Eisai R&D Management Co., Ltd.	Medicinal composition with improved stability and reduced gelation properties
AU2006231646A1 (en) *	2005-04-06	2006-10-12	Exelixis, Inc.	C-Met modulators and methods of use
TW200740820A (en) *	2005-07-05	2007-11-01	Takeda Pharmaceuticals Co	Fused heterocyclic derivatives and use thereof
EP1925941B1 (en) *	2005-08-01	2012-11-28	Eisai R&D Management Co., Ltd.	Method for prediction of the efficacy of vascularization inhibitor
WO2007015578A1 (ja)	2005-08-02	2007-02-08	Eisai R & D Management Co., Ltd.	血管新生阻害物質の効果を検定する方法
US7704990B2 (en)	2005-08-25	2010-04-27	The Trustees Of Columbia University In The City Of New York	Agents for preventing and treating disorders involving modulation of the RyR receptors
KR100990590B1 (ko) *	2005-09-01	2010-10-29	에자이 알앤드디 매니지먼트 가부시키가이샤	붕해성이 개선된 의약 조성물의 제조 방법
AU2006309551B2 (en) *	2005-11-07	2012-04-19	Eisai R & D Management Co., Ltd.	Use of combination of anti-angiogenic substance and c-kit kinase inhibitor
WO2007061127A1 (ja) *	2005-11-22	2007-05-31	Eisai R & D Management Co., Ltd.	多発性骨髄腫に対する抗腫瘍剤
CA2652442C (en) *	2006-05-18	2014-12-09	Eisai R & D Management Co., Ltd.	Antitumor agent for thyroid cancer
WO2008001956A1 (en) *	2006-06-29	2008-01-03	Eisai R & D Management Co., Ltd.	Therapeutic agent for liver fibrosis
US8865737B2 (en)	2006-08-28	2014-10-21	Eisai R&D Management Co., Ltd.	Antitumor agent for undifferentiated gastric cancer
US8962655B2 (en) *	2007-01-29	2015-02-24	Eisai R&D Management Co., Ltd.	Composition for treatment of undifferentiated gastric cancer
WO2009026717A1 (en)	2007-08-29	2009-03-05	Methylgene Inc.	Inhibitors of protein tyrosine kinase activity
KR101513326B1 (ko)	2007-11-09	2015-04-17	에자이 알앤드디 매니지먼트 가부시키가이샤	혈관 신생 저해 물질과 항종양성 백금 착물의 병용
WO2009096377A1 (ja) *	2008-01-29	2009-08-06	Eisai R & D Management Co., Ltd.	血管阻害物質とタキサンとの併用
CN106146484A (zh)	2008-03-17	2016-11-23	埃姆比特生物科学公司	喹唑啉衍生物作为raf激酶调节剂以及它们的方法和用途
US8877776B2 (en)	2009-01-16	2014-11-04	Exelixis, Inc.	(L)-malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
UA108618C2 (uk)	2009-08-07	2015-05-25		Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
ME02359B (me)	2009-08-19	2016-06-20	Eisai R&D Man Co Ltd	Farmaceutska kompozicija koja sadrži derivate hinolina
US7998973B2 (en) *	2009-11-13	2011-08-16	Aveo Pharmaceuticals, Inc.	Tivozanib and temsirolimus in combination
RU2560683C2 (ru)	2010-06-25	2015-08-20	Эйсай Ар Энд Ди Менеджмент Ко., Лтд.	Противоопухолевое средство, задействующее соединения с ингибирующим эффектом к киназам в комбинации
EP2594566A4 (en) *	2010-07-16	2014-10-01	Kyowa Hakko Kirin Co Ltd	AROMATIC HETEROCYCLIC NITROGEN CYCLE DERIVATIVE
US20130197016A1 (en)	2010-10-27	2013-08-01	Mitchell Brigell	Dosing regimes for the treatment of ocular vascular disease
EP2700403B1 (en)	2011-04-18	2015-11-25	Eisai R&D Management Co., Ltd.	Therapeutic agent for tumor
ES2841809T3 (es)	2011-06-03	2021-07-09	Eisai R&D Man Co Ltd	Biomarcadores para pronosticar y evaluar el grado de respuesta de sujetos con cáncer de tiroides y de riñón a compuestos de lenvatinib
CN102532116B (zh) *	2011-08-09	2015-01-21	武汉迈德森医药科技有限公司	抗肿瘤靶向治疗药物tivozanib的合成方法
CN102408411B (zh) *	2011-09-19	2014-10-22	北京康辰药业股份有限公司	一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用
CN102408418A (zh) *	2011-10-21	2012-04-11	武汉迈德森医药科技有限公司	Tivozanib酸性盐及其制备方法和晶型
EP2626073A1 (en)	2012-02-13	2013-08-14	Harmonic Pharma	Compound for use in the prevention and/or treatment of a neurogenerative disease or a disease involving an activation of phosphodiesterase-4 (PDE4)
BR112015009004A8 (pt)	2012-12-21	2021-07-20	Eisai R&D Man Co Ltd	forma amorfa de derivado de quinolina e método de produção da mesma
MX368099B (es)	2013-05-14	2019-09-19	Eisai R&D Man Co Ltd	Biomarcadores para predecir y evaluar el grado de respuesta de sujetos con cancer de endometrio a compuestos de tipo lenvatinib.
LT4374873T (lt)	2013-07-12	2025-12-29	Astellas Us Llc	Agentas, skirtas panaudoti oftalmologinių būklių gydymui ir profilaktikai
JO3783B1 (ar)	2014-08-28	2021-01-31	Eisai R&D Man Co Ltd	مشتق كوينولين عالي النقاء وطريقة لإنتاجه
EP3789027A1 (en)	2015-01-13	2021-03-10	Kyoto University	Bosutinib, sunitinib, tivozanib, imatinib, nilotinib, rebastinib or bafetinib for preventing and/or treating amyotrophic lateral sclerosis
JP6792546B2 (ja)	2015-02-25	2020-11-25	エーザイ・アール・アンド・ディー・マネジメント株式会社	キノリン誘導体の苦味抑制方法
CA2978226C (en)	2015-03-04	2025-02-18	Eisai R&D Management Co., Ltd.	COMBINATION OF A PD-1 ANTAGONIST AND A VEGFR/FGFR/RET TYROSINE KINASE INHIBITOR TO TREAT CANCER
JP6757959B2 (ja)	2015-06-16	2020-09-23	株式会社ＰＲＩＳＭＢｉｏＬａｂ	抗がん剤
RU2718048C2 (ru)	2015-08-20	2020-03-30	Эйсай Ар Энд Ди Менеджмент Ко., Лтд.	Противоопухолевое терапевтическое средство
MX2018004109A (es)	2015-10-05	2018-09-27	Univ Columbia	Activadores de flujo autofágico y fosfolipasa d y depuración de acumulaciones de proteína que incluyen tau y tratamiento de proteinopatías.
WO2018028591A1 (zh) *	2016-08-09	2018-02-15	殷建明	一种喹啉衍生物及其用途
CN106478621B (zh) *	2016-09-30	2018-12-25	遵义医学院	喹啉或喹唑啉类衍生物、制备方法及其应用
US10799503B2 (en)	2016-12-01	2020-10-13	Ignyta, Inc.	Methods for the treatment of cancer
CN108341813B (zh) *	2017-01-24	2020-11-17	四川大学	取代的1-(异恶唑-3-基)-3-(3-氟-4-苯基)脲衍生物及其制备方法和用途
ES2971448T3 (es)	2017-02-08	2024-06-05	Eisai R&D Man Co Ltd	Composición farmacéutica para el tratamiento de tumores
CN108530455B (zh) *	2017-03-01	2021-01-12	北京赛特明强医药科技有限公司	脲取代的芳环连二噁烷并喹唑啉类化合物或药用盐或水合物及作为酪氨酸激酶抑制剂的应用
ES2887261T3 (es) *	2017-04-27	2021-12-22	Astrazeneca Ab	Compuestos de fenoxiquinazolina y su uso para tratar el cáncer
WO2018197642A1 (en)	2017-04-27	2018-11-01	Astrazeneca Ab	C5-anilinoquinazoline compounds and their use in treating cancer
MX2019013014A (es)	2017-05-16	2020-08-06	Eisai R&D Man Co Ltd	Tratamiento de carcinoma hepatocelular.
CN109553612B (zh) *	2017-09-26	2021-09-03	广西梧州制药（集团）股份有限公司	一种吡唑并嘧啶衍生物及其制备方法和在药物制备中的用途
US11479559B2 (en)	2018-02-11	2022-10-25	Beijing Scitech-Mq Pharmaceuticals Limited	Urea-substituted aromatic ring-linked dioxinoquinoline compounds, preparation method and uses thereof
AU2019375972B2 (en)	2018-11-05	2025-08-14	Aveo Pharmaceuticals, Inc.	Use of tivozanib to treat subjects with refractory cancer
JPWO2020130125A1 (ja)	2018-12-21	2021-11-04	第一三共株式会社	抗体−薬物コンジュゲートとキナーゼ阻害剤の組み合わせ
KR20240115979A (ko)	2021-11-08	2024-07-26	프로젠토스 테라퓨틱스, 인크.	혈소판-유래 성장 인자 수용체(pdgfr) 알파 억제제 및 이의 용도
WO2023096651A1 (en)	2021-11-26	2023-06-01	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Methods for treating bile duct cancers with tivozanib
EP4531927A1 (en)	2022-05-24	2025-04-09	Daiichi Sankyo Company, Limited	Dosage regimen of an anti-cdh6 antibody-drug conjugate
WO2024095127A1 (en)	2022-10-31	2024-05-10	Pliva Hrvatska D.O.O.	Solid state forms of tivozanib and process for preparation thereof
WO2024110606A1 (en)	2022-11-25	2024-05-30	Synthon B.V.	A process for preparation of cabozantinib or tivozanib
WO2025120654A1 (en) *	2023-12-05	2025-06-12	Natco Pharma Limited	An improved process for the preparation of tivozanib hydrochloride hydrate
WO2025253311A1 (en)	2024-06-04	2025-12-11	Hetero Labs Limited	1,2-dicarboxamide compounds as kinase inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2728878B2 (ja)	1987-12-15	1998-03-18	大倉工業株式会社	中空押出成形板
GB9000644D0 (en) *	1990-01-11	1990-03-14	Erba Carlo Spa	New ureido derivatives of poly-4-amino-2-carboxy-1-methyl compounds
EP0860433B1 (en) *	1995-11-07	2002-07-03	Kirin Beer Kabushiki Kaisha	Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of growth factor receptor originating in platelet and pharmaceutical compositions containing the same
JP4194678B2 (ja)	1997-11-28	2008-12-10	キリンファーマ株式会社	キノリン誘導体およびそれを含む医薬組成物
DE1041982T1 (de) *	1997-12-22	2001-06-07	Bayer Corp., Pittsburgh	HEMMUNG DER p38 KINASE AKTIVITÄT DURCH SUBSTITUIERTEN HETEROCYCLISCHEN HARNSTOFFEN
PL205321B1 (pl)	1997-12-22	2010-04-30	Bayer Corp	Zastosowanie podstawionych heterocyklicznych moczników do wytwarzania leku do hamowania kinazy raf, podstawione heterocykliczne moczniki oraz kompozycja farmaceutyczna je zawierająca
WO2000043366A1 (en)	1999-01-22	2000-07-27	Kirin Beer Kabushiki Kaisha	Quinoline derivatives and quinazoline derivatives
US7135466B2 (en)	1999-12-24	2006-11-14	Kirin Beer Kabushiki Kaisha	Quinoline and quinazoline derivatives and drugs containing the same
JP2002030083A (ja)	2000-07-18	2002-01-29	Kirin Brewery Co Ltd	Ｎ−（２−クロロ−４−｛［６−メトキシ−７−（３−ピリジルメトキシ）−４−キノリル］オキシ｝フェニル）−ｎ’−プロピルウレアの二塩酸塩
DE60137273D1 (de) *	2000-10-20	2009-02-12	Eisai R&D Man Co Ltd	Verfahren zur Herstellung von 4-Phenoxy chinolin Derivaten
WO2002088110A1 (en) *	2001-04-27	2002-11-07	Kirin Beer Kabushiki Kaisha	Quinoline derivative having azolyl group and quinazoline derivative

2002
- 2002-04-26 WO PCT/JP2002/004279 patent/WO2002088110A1/ja not_active Ceased
- 2002-04-26 CN CNB028126246A patent/CN1273466C/zh not_active Expired - Lifetime
- 2002-04-26 ES ES02724651T patent/ES2256466T3/es not_active Expired - Lifetime
- 2002-04-26 CA CA2445333A patent/CA2445333C/en not_active Expired - Lifetime
- 2002-04-26 US US10/132,473 patent/US6821987B2/en not_active Expired - Lifetime
- 2002-04-26 AU AU2002255284A patent/AU2002255284B2/en not_active Expired
- 2002-04-26 EP EP05028370A patent/EP1652847B1/en not_active Expired - Lifetime
- 2002-04-26 TW TW091108719A patent/TWI324154B/zh not_active IP Right Cessation
- 2002-04-26 NZ NZ529046A patent/NZ529046A/en not_active IP Right Cessation
- 2002-04-26 KR KR1020037013939A patent/KR100879669B1/ko not_active Expired - Lifetime
- 2002-04-26 DE DE60226912T patent/DE60226912D1/de not_active Expired - Lifetime
- 2002-04-26 DE DE60208364T patent/DE60208364T2/de not_active Expired - Lifetime
- 2002-04-26 AT AT05028370T patent/ATE396988T1/de not_active IP Right Cessation
- 2002-04-26 PL PL367105A patent/PL209822B1/pl unknown
- 2002-04-26 DK DK02724651T patent/DK1382604T3/da active
- 2002-04-26 BR BRPI0209216A patent/BRPI0209216B8/pt not_active IP Right Cessation
- 2002-04-26 RU RU2003134376/04A patent/RU2283841C2/ru active
- 2002-04-26 IL IL15845902A patent/IL158459A0/xx active IP Right Grant
- 2002-04-26 EP EP02724651A patent/EP1382604B1/en not_active Expired - Lifetime
- 2002-04-26 MX MXPA03009662A patent/MXPA03009662A/es active IP Right Grant
2003
- 2003-10-08 ZA ZA200307861A patent/ZA200307861B/en unknown
- 2003-10-14 NO NO20034595A patent/NO326325B1/no not_active IP Right Cessation
2004
- 2004-06-07 US US10/861,446 patent/US7211587B2/en not_active Expired - Fee Related
2009
- 2009-10-21 JP JP2009242477A patent/JP2010077131A/ja not_active Withdrawn
2018
- 2018-01-31 NL NL300927C patent/NL300927I9/nl unknown
- 2018-02-05 NO NO2018005C patent/NO2018005I1/no unknown
- 2018-02-06 FR FR18C1006C patent/FR18C1006I2/fr active Active
- 2018-02-08 BE BE2018C008C patent/BE2018C008I2/nl unknown

Also Published As

Publication number	Publication date
FR18C1006I1 (fr)	2018-03-16
DE60226912D1 (de)	2008-07-10
DK1382604T3 (da)	2006-04-18
ATE396988T1 (de)	2008-06-15
MXPA03009662A (es)	2004-12-06
NO2018005I1 (no)	2018-02-05
US6821987B2 (en)	2004-11-23
DE60208364T2 (de)	2006-09-28
EP1382604A4 (en)	2004-09-08
EP1652847B1 (en)	2008-05-28
CN1543459A (zh)	2004-11-03
TWI324154B (it)	2010-05-01
BRPI0209216B8 (pt)	2021-05-25
ES2256466T3 (es)	2006-07-16
CN1273466C (zh)	2006-09-06
WO2002088110A1 (en)	2002-11-07
EP1382604B1 (en)	2005-12-28
NL300927I1 (nl)	2018-12-04
IL158459A0 (en)	2004-05-12
JP2010077131A (ja)	2010-04-08
NL300927I9 (nl)	2019-02-05
FR18C1006I2 (fr)	2019-03-01
NO20034595L (no)	2003-12-19
RU2283841C2 (ru)	2006-09-20
DE60208364D1 (de)	2006-02-02
US20040229876A1 (en)	2004-11-18
NO20034595D0 (no)	2003-10-14
NO326325B1 (no)	2008-11-10
PL367105A1 (en)	2005-02-21
US20030087907A1 (en)	2003-05-08
BRPI0209216B1 (pt)	2017-05-30
KR100879669B1 (ko)	2009-01-21
CA2445333C (en)	2011-03-22
EP1652847A3 (en)	2006-08-02
PL209822B1 (pl)	2011-10-31
HK1070649A1 (en)	2005-06-24
US7211587B2 (en)	2007-05-01
NZ529046A (en)	2005-10-28
RU2003134376A (ru)	2005-04-20
ZA200307861B (en)	2004-10-08
EP1382604A1 (en)	2004-01-21
EP1652847A1 (en)	2006-05-03
AU2002255284B2 (en)	2007-10-04
KR20040015143A (ko)	2004-02-18
BR0209216A (pt)	2004-07-06
CA2445333A1 (en)	2002-11-07

Publication	Publication Date	Title
BE2018C008I2 (it)	2021-02-04
AP1753A (en)	2007-07-18	Thiophene derivatives as antiviral agents for flavvivirus infection
ZA200309887B (en)	2004-07-20	Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents.
DK0918776T3 (da)	2004-07-12	Totalsyntese af antitumor acylfulvener
EA200300982A1 (ru)	2004-12-30	Гетероциклические производные для лечения рака и других пролиферативных заболеваний
DE69529619D1 (en)	2003-03-20	Pyrimidinylpyrazolderivate
PT1362854E (pt)	2008-01-21	Derivados benzo[b]tiofeno e processos para o produzir
FI952420A0 (fi)	1995-05-18	Glukopyranosidibentsotiofeenit
MXPA03006057A (es)	2004-01-26	Proceso para preparar (+) trans-4-p-fluorofenil -3 hidroximetil.
EP1251129A4 (en)	2003-03-05	PYRIMIDINE DERIVATIVES WITH ANTI-TUMOR EFFECT
EP1466900A4 (en)	2005-07-20	DERIVATIVES OF VITAMIN D-DOUBLE SUBSTITUTION